濮阳东方妇科医院做人流收费比较低濮阳东方医院男科治阳痿评价比较高,濮阳东方男科在线挂号,濮阳东方医院男科治早泄价格收费低,濮阳东方医院男科好不好啊,濮阳东方看妇科好么,濮阳东方医院男科治疗阳痿口碑评价很好,濮阳东方看男科病技术先进

SAN DIEGO (KGTV) -- The California Highway Patrol is investigating after a body was found on Interstate 5 near Camp Pendleton Thursday afternoon.According to CHP, the body of a 51-year-old man was found on the exit ramp from I-5 north to Christianitos Road.Once officers arrived, they found the San Clemente man out of view in the brush next to the road.The San Diego County Medical Examiner responded to the scene and is trying to determine the cause of death. Anyone with information is asked to call CHP at 858-637-3800. 531

SAN DIEGO (KGTV) -- The California Independent System Operator again Sunday reminded consumers throughout the state conserve energy, warning of more possible rotating outages.SDG&E said early in the day Sunday that customers should be prepared for possible outages to be called from 4 p.m. to 9 p.m.The news comes after a flex alert was issued statewide from 3 p.m. to 9 p.m. daily through Monday, September 7.“Energy conservation is essential in helping reduce the possibility of widespread rotating outages and the number of people impacted. Understandably, it may be difficult to reduce energy use during the high temperatures and the ongoing pandemic. However, everyone is urged to do their part to cut back on energy use, if health and safety permits, during this critical time,” SDG&E wrote.Just before 6:30 p.m., CAISO issued a Stage 2 emergency and warned that consumers should conserve power until 9 p.m. to avoid rolling outages. Stage 2 is the step before rolling outages are ordered.The energy provider said turning off air conditioners, avoiding the use of the dishwasher, clothes washers and dryers, and switching off unused lighting can all help conserve energy.SDG&E also said the Valley Fire, which has currently burned 1,500 acres near Alpine, has impacted electrical equipment and caused power outages.SDG&E said it’s working with Cal Fire in an effort to restore power quickly. 1421

SAN DIEGO (KGTV) -- The man accused of killing his stepmother and burying her body in the backyard of a Tijuana home pleaded guilty to unrelated drug charges Tuesday. Aaron Seth Juarez, 20, pleaded guilty to possession of heroin for sale and agreed to a two-year state prison sentence. Juarez was taken into custody in San Diego earlier this month for probation violations. He’s also wanted by the Deputy Attorney General of Justice in Tijuana on suspicion of killing Fernanda González Serrano in February.RELATED: Man suspected of killing stepmother found in Tijuana backyard arrestedGonzález was last heard from on Feb. 2. Shortly after her disappearance, her husband was treated for a gunshot wound in San Diego, but was reportedly unable to answer any questions.After posting on social media in search of González, her sister, Erika, received a call not to keep searching, and that González, "was already dead and in the back of her yard."Erika and her father went to González’ Tijuana home and started digging in the backyard, where they discovered González’ body.RELATED: Man accused of killing, burying stepmom in Tijuana appears in courtMexican police believed Juarez may have returned to the U.S. on Feb. 23. 1225

SAN DIEGO (KGTV) — The commissioner of the Pac-12 says 15-minute testing technology from a San Diego company could be the “game-changer” needed to restart competition in the conference before the end of the year.The Pac-12 is considering restarting college football as early as mid- to late-November, according to ESPN, as long as it can secure approvals from state and county lawmakers in California and Oregon.In some conferences, college football is entering its third week, but Pac-12 schools like USC and UCLA are still in workout mode after the conference voted last month to postpone all sports until 2021 at the earliest.League officials are now revisiting that decision and considering an earlier timeline after signing an agreement with San Diego-based Quidel Corporation to provide rapid antigen testing for all athletes, including daily tests for high-contact sports like football.“The access to rapid result testing that we can implement on even a daily basis with some sports with high contact will be a real game changer for us,” Pac-12 commissioner Larry Scott said after touring Quidel’s facility this month.Most nasal swab tests are genetic tests, or PCR tests, which seek out the genetic code buried inside the virus’ protein shell. These tests are considered the industry standard, but they require processing in a lab to convert RNA into enough readable strands of DNA. Results can sometimes take days.Quidel’s nasal swab test is what’s called an antigen test, which looks for parts of the virus’ protein shell. It can be read by machines at each university in about 15 minutes.“No one's going to be spreading the virus because no one will be engaging in practice or competition with the virus,” Scott said.That’s the hope at least, but the partnership with the Pac-12 will be an important test for Quidel’s diagnostic product.Quidel was the first company to get a rapid antigen test on the market, securing an emergency use authorization in May. But there were questions about the accuracy of the test compared to PCR tests in the small sample size provided by the company.In July, Quidel published more data showing its antigen tests matched up with PCR tests 96.7% of the time when a positive was detected. But those results were only among individuals who were actually showing symptoms.“The question that people have is in the asymptomatic population, will the data look similar?” said Quidel CEO Doug Bryant in an interview.Bryant said the company has unpublished data that will be forwarded to the FDA showing “very similar” relative accuracy to PCR tests in asymptomatic individuals, but he said the goal of the partnership with the Pac-12 is to investigate the tests even further.“We want to know that the tests we’re doing are appropriate for use in the asymptomatic population. And we need to demonstrate that, to not only the scientific community but to the public at large,” Bryant said.The testing program with the Pac-12 will essentially be a large clinical trial to find out if rapid testing of athletes can prevent spread, backed by the muscle at some of the premiere research universities.The Pac-12 is hoping the testing program will convince lawmakers to ease restrictions on college athletics, particularly in California.Although the NFL played a game at the new SoFI Stadium in Inglewood last weekend, nearby USC cannot gather in groups of more than 12 players.There are now four antigen tests on the market. Quidel plans to roll out its Sofia 2 testing machines to Pac-12 universities later this month. 3554

SAN DIEGO (KGTV) — The Department of Defense has awarded a San Diego biotech company up to million to help develop a next-generation drug to fight COVID-19.Sorrento Therapeutics calls the drug a “rapid countermeasure” against the disease, one that might serve as a vaccine substitute in certain populations or a critical stopgap tool if the virus mutates.“With this, we have a new platform potentially that can respond very quickly to any type of emerging threat,” said CEO Dr. Henry Ji.Sorrento is trying to become the first company to develop an approved DNA-encoded monoclonal antibody treatment. The approach is similar to the experimental monoclonal antibody treatment used on President Trump, but Sorrento’s concept is a more advanced version that offers several benefits.Sorrento’s drug is designed to be used as either a treatment in infected patients or a fast-forming layer of defense in healthy people. The company said its solution should be cheaper and easier to deploy than existing monoclonal antibodies, while offering vaccine-like protective effects that last for several months rather than just two or three weeks.Antibodies are one of the body’s key defense mechanisms. They seek out pathogens and bind to them, marking the invader for destruction like ground troops marking an enemy base for an airstrike. In some cases, antibodies can even neutralize an invader themselves by blocking its method of entry into cells.Monoclonal antibodies are antibodies designed by scientists to neutralize a pathogen. They are hand-picked, genetically modified super antibodies that are cloned in labs.However, the process of growing these super soldiers in the lab is difficult, transporting them requires a cold chain, and as a result, monoclonal antibodies are among the most expensive drugs in the world.Instead of giving people an infusion of pre-made antibodies, Sorrento’s idea is to give people a shot of DNA that instructs some of their cells to churn out perfectly pre-designed antibodies.“It's much easier to make enough DNA to treat a large number of people than it is to make enough protein to treat a large number of people. That’s just a fact about manufacturing,” said Dr. Robert Allen, Sorrento’s chief scientific officer on the project.Dr. Allen said the company is hopeful the drug will induce cells to make protective antibodies for six months or more.This DNA approach to an antibody treatment has never been approved for any disease but other companies are working on their own versions of it. Another biotech with ties to San Diego, Inovio Pharmaceuticals, became the first company to test this approach in humans in 2019 for a drug targeting the Zika virus.Sorrento’s approach is similar to the way DNA vaccines work, but it cuts out intermediary steps and jumpstarts the production of antibodies, rather than leaving the production of antibodies up to the body’s immune system. The result is that protective antibodies can start circulating in days after injection rather than weeks, the company said.“What this is capable of doing is it bypasses the need for the immune system,” said Dr. Mark Brunswick, Sorrento’s senior vice president for regulatory affairs.The drug is unlikely to replace a vaccine in most situations because vaccines can produce other defense mechanisms like T-cells that work in conjunction with antibodies. But the drug might work better than a vaccine for the elderly and others with weakened immune systems who are unable to produce a robust number of antibodies on their own, Brunswick said.Still, the company still has a lot of pre-clinical work and testing to go. Sorrento is hoping to have the drug ready for human trials in four to six months.By then, vaccines from Pfizer and Moderna will likely be widely available, but Dr. Ji said the world needs to prepare for the possibility this virus will mutate.“When you vaccinate hundreds of millions, potentially billions of people, the virus is under tremendous evolution pressure,” he said. “It will escape. It’s guaranteed that the virus is going to mutate and escape all of the vaccines we’re trying to create.”If it does, he said Sorrento will be ready to rapidly deploy its DNA-based countermeasure. 4223